Lumicitabine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lumicitabine
Accession Number
DB14808
Type
Small Molecule
Groups
Investigational
Description

Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).

Structure
Thumb
Synonyms
  • ALS-008176
Categories
UNII
BNW5PQ52G1
CAS number
1445385-02-3
Weight
Average: 433.86
Monoisotopic: 433.1415914
Chemical Formula
C18H25ClFN3O6
InChI Key
MJVKYGMNSQJLIN-KYZVSKTDSA-N
InChI
InChI=1S/C18H25ClFN3O6/c1-9(2)15(24)27-8-18(7-19)13(28-16(25)10(3)4)12(20)14(29-18)23-6-5-11(21)22-17(23)26/h5-6,9-10,12-14H,7-8H2,1-4H3,(H2,21,22,26)/t12-,13+,14-,18-/m1/s1
IUPAC Name
[(2R,3R,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-(chloromethyl)-4-fluoro-3-[(2-methylpropanoyl)oxy]oxolan-2-yl]methyl 2-methylpropanoate
SMILES
CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
58171803
ChEMBL
CHEMBL3417258
ZINC
ZINC000147003908
Wikipedia
Lumicitabine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableInfections, Respiratory Syncytial Virus1
1CompletedBasic ScienceInfections, Respiratory Syncytial Virus1
1CompletedOtherHealthy Volunteers1
1CompletedOtherImpaired kidney function1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentInfections, Respiratory Syncytial Virus2
1TerminatedOtherHealthy Volunteers1
2CompletedOtherInfections, Respiratory Syncytial Virus1
2CompletedTreatmentInfections, Respiratory Syncytial Virus2
2TerminatedTreatmentRespiratory Syncytial Virus (RSV)2
2WithdrawnTreatmentMetapneumovirus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.063 mg/mLALOGPS
logP2.11ALOGPS
logP2.05ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)19.22ChemAxon
pKa (Strongest Basic)3.82ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area120.52 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity98.79 m3·mol-1ChemAxon
Polarizability41.59 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:28 / Updated on March 01, 2020 21:56

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates